As of 2024-07-27, the EV/EBITDA ratio of Rigel Pharmaceuticals Inc (RIGL) is -13.11. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RIGL's latest enterprise value is 222.89 mil USD. RIGL's TTM EBITDA according to its financial statements is -17.00 mil USD. Dividing these 2 quantities gives us the above RIGL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.0x - 18.7x | 13.2x |
| Forward P/E multiples | 14.2x - 22.8x | 19.0x |
| Fair Price | (15.69) - (20.07) | (17.53) |
| Upside | -246.0% - -286.7% | -263.1% |
| Date | EV/EBITDA |
| 2024-07-26 | -13.11 |
| 2024-07-25 | -13.26 |
| 2024-07-24 | -12.88 |
| 2024-07-23 | -12.88 |
| 2024-07-22 | -12.45 |
| 2024-07-19 | -11.98 |
| 2024-07-18 | -11.94 |
| 2024-07-17 | -12.70 |
| 2024-07-16 | -13.63 |
| 2024-07-15 | -12.94 |
| 2024-07-12 | -12.31 |
| 2024-07-11 | -11.94 |
| 2024-07-10 | -10.88 |
| 2024-07-09 | -10.41 |
| 2024-07-08 | -10.13 |
| 2024-07-05 | -10.04 |
| 2024-07-03 | -9.99 |
| 2024-07-02 | -10.70 |
| 2024-07-01 | -10.69 |
| 2024-06-28 | -10.50 |
| 2024-06-27 | -11.85 |
| 2024-06-26 | -10.17 |
| 2024-06-25 | -10.71 |
| 2024-06-24 | -11.88 |
| 2024-06-21 | -11.82 |
| 2024-06-20 | -11.87 |
| 2024-06-18 | -11.33 |
| 2024-06-17 | -11.57 |
| 2024-06-14 | -11.85 |
| 2024-06-13 | -12.06 |
| 2024-06-12 | -12.33 |
| 2024-06-11 | -12.54 |
| 2024-06-10 | -12.54 |
| 2024-06-07 | -11.82 |
| 2024-06-06 | -11.92 |
| 2024-06-05 | -12.10 |
| 2024-06-04 | -12.07 |
| 2024-06-03 | -12.16 |
| 2024-05-31 | -12.10 |
| 2024-05-30 | -11.68 |
| 2024-05-29 | -11.48 |
| 2024-05-28 | -11.63 |
| 2024-05-24 | -11.38 |
| 2024-05-23 | -11.33 |
| 2024-05-22 | -11.53 |
| 2024-05-21 | -11.45 |
| 2024-05-20 | -11.87 |
| 2024-05-17 | -11.82 |
| 2024-05-16 | -12.15 |
| 2024-05-15 | -12.02 |